Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | KDM4B | O94953 | 2/20 | 0.32 |
| ▸ | KDM5C | P41229 | 2/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970025 | 0.81 | KDM4A (0.38) | EGLN1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL17372319 | 0.81 | LOXL2 (0.40) | EGLN1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL4523578 | 0.77 | HTR2A (0.33) | EGLN1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL127024 | 0.74 | AXL (0.48) | EGLN1AXLPRKCIKDM4AKDM4B | |
| SCHEMBL29424891 | 0.74 | AXL (0.48) | EGLN1AXLPRKCIKDM4AKDM4B | |
| Water SCHEMBL10628541 | 0.72 | AXL (0.47) | EGLN1AXLPRKCIKDM4AKDM4B | |
| SCHEMBL18924527 | 0.71 | UTS2R (0.30) | — | |
| SCHEMBL4767690 | 0.69 | PARP1 (0.43) | EGLN1AXLPRKCIKDM4AKDM4B | |
| SCHEMBL21856245 | 0.69 | MAPK1 (0.52) | EGLN1AXLPRKCIKDM4AKDM4B | |
| SCHEMBL21912960 | 0.69 | MAPK1 (0.35) | EGLN1AXLPRKCIKDM4AKDM4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-1670798-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | Altana Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061496-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | NOS2, NOS1, NOS3 | EGLN1 879/4885AXL 3917/4885PRKCI 1161/4885 |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | EGLN1 879/4885AXL 3917/4885PRKCI 1161/4885 |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | NOS2, NOS1, NOS3 | EGLN1 673/4885AXL 3304/4885PRKCI 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.